Tools to improve clinical trial design in urothelial cancer

Authors

  • Allison M. Deal MS,

    1. Biostatistics and Clinical Data Management Core, University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
    Search for more papers by this author
  • Matthew I. Milowsky MD

    Corresponding author
    1. Department of Medicine, Division of Hematology and Medical Oncology, University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
    • Corresponding author: Matthew I. Milowsky, MD, Division of Hematology and Oncology, University of North Carolina at Chapel Hill, third Floor Physician's Office Building, 170 Manning Drive, Chapel Hill, NC 27599; Fax: (919) 966-6735; matt_milowsky@med.unc.edu

    Search for more papers by this author

Abstract

Two reports in this issue describe a nomogram for predicting survival and a landmark analysis demonstrating the relation between 6-month and 9-month progression-free status and overall survival in patients with metastatic urothelial cancer. These 2 important tools will be used to improve future clinical trial design in patients with advanced urothelial cancer.

Ancillary